Sterna Biologicals is an innovative clinical-stage immunology company developing novel treatments for severe chronic inflammatory diseases. By targeting transcription factors, such as GATA-3, that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company’s proprietary DNAzyme-based drug candidates can address  diseases like severe asthma and ulcerative colitis more effectively. For further information, please visit www.sterna-biologicals.com.